Total Payments
$374,226
2024 Payments
$46,672
Companies
15
Transactions
306
Payment Breakdown by Category
Consulting$174,020 (46.5%)
Other$86,263 (23.1%)
Research$59,287 (15.8%)
Travel$46,474 (12.4%)
Food & Beverage$8,182 (2.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $174,020 | 39 | 46.5% |
| Unspecified | $59,287 | 45 | 15.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $49,791 | 26 | 13.3% |
| Travel and Lodging | $46,474 | 82 | 12.4% |
| Honoraria | $36,472 | 8 | 9.7% |
| Food and Beverage | $8,182 | 106 | 2.2% |
Payments by Type
General
$314,940
261 transactions
Research
$59,287
45 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| CSL Behring | $79,873 | 50 | $0 (2024) |
| BIOVERATIV THERAPEUTICS INC. | $49,985 | 44 | $0 (2020) |
| Novo Nordisk Inc | $46,151 | 26 | $0 (2024) |
| BioMarin Pharmaceutical Inc. | $36,552 | 23 | $0 (2024) |
| Shire North American Group Inc | $35,392 | 26 | $0 (2019) |
| Genentech USA, Inc. | $26,525 | 29 | $0 (2024) |
| GENZYME CORPORATION | $22,866 | 16 | $0 (2024) |
| HEMA Biologics, LLC | $21,299 | 34 | $0 (2023) |
| F. Hoffmann-La Roche AG | $19,820 | 13 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $14,670 | 6 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $46,672 | 24 | BioMarin Pharmaceutical Inc. ($17,803) |
| 2023 | $28,405 | 36 | HEMA Biologics, LLC ($14,140) |
| 2022 | $51,719 | 51 | Takeda Pharmaceuticals U.S.A., Inc. ($11,470) |
| 2021 | $11,460 | 10 | Genentech USA, Inc. ($6,882) |
| 2020 | $37,990 | 14 | CSL Behring ($16,294) |
| 2019 | $84,328 | 74 | CSL Behring ($20,540) |
| 2018 | $93,764 | 67 | Shire North American Group Inc ($25,149) |
| 2017 | $19,890 | 30 | Bayer HealthCare Pharmaceuticals Inc. ($12,817) |
All Payment Transactions
306 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | F. Hoffmann-La Roche AG | Hemlibra (Biological) | — | In-kind items and services | $4,144.63 | Research |
| Study: An open label study to determine PK and PD of Hemlibra in severe hemophilia A without inhibitors • Category: Hematology | ||||||
| 12/31/2024 | BioMarin Pharmaceutical Inc. | — | Consulting Fee | Cash or cash equivalent | $2,967.18 | General |
| 12/31/2024 | BioMarin Pharmaceutical Inc. | — | Consulting Fee | Cash or cash equivalent | $2,967.18 | General |
| 12/31/2024 | BioMarin Pharmaceutical Inc. | — | Consulting Fee | Cash or cash equivalent | $2,967.18 | General |
| 12/31/2024 | BioMarin Pharmaceutical Inc. | — | Consulting Fee | Cash or cash equivalent | $2,967.18 | General |
| 12/31/2024 | BioMarin Pharmaceutical Inc. | — | Consulting Fee | Cash or cash equivalent | $2,967.18 | General |
| 12/31/2024 | BioMarin Pharmaceutical Inc. | — | Consulting Fee | Cash or cash equivalent | $2,967.18 | General |
| 12/31/2024 | F. Hoffmann-La Roche AG | Hemlibra (Biological) | — | In-kind items and services | $1,970.25 | Research |
| Study: An open label study to determine PK and PD of Hemlibra in severe hemophilia A without inhibitors • Category: Hematology | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | Hemlibra (Biological) | — | In-kind items and services | $438.50 | Research |
| Study: ATHN 7 • Category: Hematology | ||||||
| 10/18/2024 | PFIZER INC. | BENEFIX (Biological), BEQVEZ | — | In-kind items and services | $330.00 | Research |
| Study: BENEFIX CLINICAL PUBLICATION PROGRAM • Category: HEMATOLOGY | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | Hemlibra (Biological) | — | In-kind items and services | $316.63 | Research |
| Study: ATHN 7 • Category: Hematology | ||||||
| 06/30/2024 | F. Hoffmann-La Roche AG | Hemlibra (Biological) | — | In-kind items and services | $1,838.75 | Research |
| Study: ATHN 7 • Category: Hematology | ||||||
| 04/23/2024 | Genentech USA, Inc. | Hemlibra (Biological) | Food and Beverage | In-kind items and services | $60.43 | General |
| Category: Hematology | ||||||
| 03/31/2024 | F. Hoffmann-La Roche AG | Hemlibra (Biological) | — | In-kind items and services | $974.50 | Research |
| Study: ATHN 7 • Category: Hematology | ||||||
| 02/27/2024 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $14,542.50 | General |
| 02/27/2024 | GENZYME CORPORATION | — | Travel and Lodging | In-kind items and services | $427.50 | General |
| 02/27/2024 | GENZYME CORPORATION | — | Travel and Lodging | In-kind items and services | $374.75 | General |
| 02/27/2024 | GENZYME CORPORATION | — | Travel and Lodging | In-kind items and services | $355.35 | General |
| 02/27/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $156.93 | General |
| 02/27/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $87.41 | General |
| 02/27/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $72.46 | General |
| 02/27/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $47.90 | General |
| 01/31/2024 | CSL Behring | ALBUMINAR-25 (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $2,135.00 | General |
| Category: Blood Bank | ||||||
| 01/01/2024 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $595.00 | General |
| 12/31/2023 | BioMarin Pharmaceutical Inc. | — | Consulting Fee | Cash or cash equivalent | $491.78 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment | BIOVERATIV THERAPEUTICS INC. | $22,234 | 14 |
| PHASE 3, PROSPECTIVE, RANDOMIZED, MULTI-CENTER CLINICAL STUDY COMPARING THE SAFETY AND EFFICACY OF BAX 855 FOLLOWING PK-GUIDED PROPHYLAXIS TARGETING TWO DIFFERENT FVIII TROUGH LEVELS IN SUBJECTS WITH SEVERE HEMOPHILIA A | Shire North American Group Inc | $9,019 | 8 |
| An open label study to determine PK and PD of Hemlibra in severe hemophilia A without inhibitors | F. Hoffmann-La Roche AG | $6,115 | 2 |
| A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP) TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 (SHP655) ADMINISTERED IN ADDITION TO STANDARD OF CARE (SOC) TREATMENT | Takeda Pharmaceuticals U.S.A., Inc. | $4,995 | 2 |
| HEMOPHILIA CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $4,760 | 3 |
| ATHN 7 | F. Hoffmann-La Roche AG | $3,568 | 4 |
| Emicizumab prophylaxis in people with hemophilia A aged ?50 years with comorbidities: experience from the ATHN 7 hemophilia natural history study | F. Hoffmann-La Roche AG | $3,512 | 2 |
| Clinical Characteristics and Outcomes of Hemophilia B Patients Managed with ALPROLIX in Routine Clinical Practice | BIOVERATIV THERAPEUTICS INC. | $1,795 | 1 |
| A Non-controlled, Open-Label, Multicenter, Study of Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Subjects With Inhibitors Undergoing the First ITI Treatment | BIOVERATIV THERAPEUTICS INC. | $1,050 | 2 |
| Prospective study (242HA201) | GENZYME CORPORATION | $750.00 | 2 |
| Retrospective chart review of hemophilia A patients with inhibitors treated with rFVIIIFc for ITI | BIOVERATIV THERAPEUTICS INC. | $648.26 | 2 |
| A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study) | BIOVERATIV THERAPEUTICS INC. | $333.33 | 1 |
| BENEFIX CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
| rFVIIIFc for first-time immune tolerance induction (ITI) therapy: Interim results from the global, prospective verITI-8 Study | BIOVERATIV THERAPEUTICS INC. | $176.67 | 1 |
About Dr. Michael Wang, MD
Dr. Michael Wang, MD is a Pediatric Hematology-Oncology healthcare provider based in Aurora, Colorado. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1588749238.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Wang, MD has received a total of $374,226 in payments from pharmaceutical and medical device companies, with $46,672 received in 2024. These payments were reported across 306 transactions from 15 companies. The most common payment nature is "Consulting Fee" ($174,020).
Ad
Practice Information
- Specialty Pediatric Hematology-Oncology
- Location Aurora, CO
- Active Since 10/25/2006
- Last Updated 07/19/2012
- Taxonomy Code 2080P0207X
- Entity Type Individual
- NPI Number 1588749238
Products in Payments
- Idelvion (Biological) $35,191
- HEMLIBRA (Biological) $32,849
- ADYNOVATE (Biological) $30,383
- ELOCTATE (Drug) $24,030
- SevenFact (Biological) $21,218
- FITUSIRAN (Drug) $17,495
- Hemlibra (Biological) $13,444
- CEPROTIN (Biological) $8,370
- HEMGENIX (Biological) $5,955
- RiaSTAP (Biological) $5,878
- Non-Covered $4,991
- Afstyla (Biological) $4,593
- Esperoct (Biological) $4,050
- NUWIQ (Biological) $2,500
- ALPROLIX (Biological) $2,493
- NovoSeven RT (Drug) $2,198
- ALBUMINAR-25 (Biological) $2,135
- VONVENDI (Biological) $1,130
- BENEFIX (Biological) $1,110
- NO PRODUCT DISCUSSED (Drug) $1,050
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatric Hematology-Oncology Doctors in Aurora
Lia Gore, Md, MD
Pediatric Hematology-Oncology — Payments: $118,426
Pediatric Hematology-Oncology $118,426
Marilyn Manco-Johnson, Md, MD
Pediatric Hematology-Oncology — Payments: $92,053
Pediatric Hematology-Oncology $92,053
Mr. Christopher Ng, M.d, M.D
Pediatric Hematology-Oncology — Payments: $42,645
Pediatric Hematology-Oncology $42,645
Beth Warren, Md, MD
Pediatric Hematology-Oncology — Payments: $31,520
Pediatric Hematology-Oncology $31,520
Rachelle Nuss, Md, MD
Pediatric Hematology-Oncology — Payments: $29,284
Pediatric Hematology-Oncology $29,284
Daniel Ambruso, Md, MD
Pediatric Hematology-Oncology — Payments: $28,920
Pediatric Hematology-Oncology $28,920